ReCode Therapeutics Presents New Preclinical Data from mRNA-based Program for Cystic Fibrosis at the ATS 2022 International Conference

MENLO PARK, Calif. & DALLAS--(BUSINESS WIRE)-- #ATS2022--Study confirms the ability of ReCode’s SORT LNP platform to deliver optimized, functional CFTR mRNA as an aerosol directly to specific cell targets.

Click to view original post